Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + dexamethasone in relapsed/refractory multiple myeloma with del(17p) or t(4;14)
2011-002081-20Phase 2Active
- Sponsor
- CHU de Lille
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by CHU de Lille. Primary endpoint: Time to disease progression. Started May 2011; status: active.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-002081-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002081-20.